RecruitingNCT05903027
Gepant treAtments: EffectIveNess and tolERability (GAINER)
Effectiveness and Tolerability of Rimegepant as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study (GAINER)
Sponsor
University of Florence
Enrollment
100 participants
Start Date
Jun 15, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III).
- At least 3 MMDs
- Good compliance to study procedures
- Availability of headache diary at least of the preceding months before enrollment
Exclusion Criteria4
- Subjects with contraindications for use of gepants;
- Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
- medical comorbidities that could interfere with study results;
- Pregnancy and breastfeeding.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRimegepant 75 MG Disintegrating Oral Tablet
Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05903027
Related Trials
NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder
NCT056697031 location
Aerobic Exercise and Its Impact on Sensory, Musculoskeletal, and Psychosocial Aspects in Migraine
NCT067164891 location
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
NCT066241372 locations
BE WELL With Migraine: Brain Education and WELLness With Migraine
NCT059875923 locations
Cannabis for the Prophylactic Treatment of Migraine
NCT039721241 location